Home / Resources / Videos / ADA 2017 / Leigh Perreault Part 6, GLP-1 And SGLT2 Medications for Pre-Diabetes Treatment

Leigh Perreault Part 6, GLP-1 And SGLT2 Medications for Pre-Diabetes Treatment

In part 6, the conclusion, of this Exclusive Interview, Dr. Leigh Perreault talks with Diabetes in Control Medical Editor Joy Pape during the ADA meeting in San Diego, California, about her recommendations regarding certain diabetes drugs as a treatment option for her prediabetes patients.

Dr. Leigh Perreault is an associate professor of medicine, physician and clinical researcher at the University of Colorahttp://www.diabetesincontrol.com/wp-admin/post.php?post=52656&action=editdo Denver School of Medicine, Aurora, CO. Her research interests include understanding the different pathways by which people develop type 2 diabetes, developing tailored strategies for diabetes prevention and the human microbiome.

Transcript of this video segment:

Joy: You mentioned prevention of cardiovascular disease in prediabetes, although not indicated at this point for people with prediabetes, do you recommend SGLT2s? Do you recommend GLP1s? Do you use those in your practice for people who don’t have diabetes?

Dr. Perreault: The shorter answer is, I wish I could. Those drugs would be absolutely ideal for those patients because they lower glucose and body weight. But generally, insurance companies will not pay for those unless people have a very clear diagnosis of diabetes. Sometimes I try and diagnose people with diabetes based on a 2-hour oral glucose tolerance test, and/or fasting glucose and/or an A1c because if I can get a diagnosis of diabetes then those things are finally at my disposal. So that said, there was a recent publication in The Lancet showing that liraglutide accelerated weight gain in people with prediabetes but also, prevented diabetes in people with prediabetes. So, the SCALE Prediabetes and Obesity Study, and that  is very clear that the weight loss and prevention of diabetes…that is what I am trying to do for my patients. Canagliflozin is also in clinical trials for the prevention of diabetes in people with prediabetes. In fact there is so much interest in the notion that we can not only prevent diabetes, but prevent the complications of diabetes in people with prediabetes that currently there are over 1,700 global trials registered for the prevention of complications of diabetes in people with prediabetes using a number of different things including GLP1, etc, analogs and SGLT2 inhibitors.

Joy: Well, I thank you for this interesting interview. We’d love to have so many other subjects to talk about, but I guess we’ll hold that for another time. Thank you.

Dr. Perreault: Thank you.

Return to the main page.